卡培他滨维持治疗老年晚期三阴性乳腺癌的效果及安全性  

Efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer

作　　者：余美剑 谭金龙 陈志刚 YU Meijian;TAN Jinlong;CHEN Zhigang(The Second Department of Oncology,Shangrao People′s Hospital,Jiangxi Province,Shangrao 334000,China)

机构地区：[1]江西省上饶市人民医院肿瘤二科,江西上饶334000

出　　处：《中国当代医药》2022年第20期92-94,共3页China Modern Medicine

基　　金：江西省卫生厅科技计划项目(20167266)。

摘　　要：目的探讨卡培他滨维持治疗老年晚期三阴性乳腺癌的效果及安全性。方法选取2016年7月至2019年7月上饶市人民医院收治的老年晚期三阴性乳腺癌患者100例为研究对象,采用随机数字表法分为对照组(50例)和观察组(50例),对照组实施多西他赛+多柔比星+环磷酰胺治疗,观察组在此基础上口服卡培他滨维持治疗,比较两组的治疗效果、无进展生存期、中位生存期与不良反应总发生率。结果观察组的治疗总有效率为88.00%,高于对照组的64.00%,差异有统计学意义(P<0.05);观察组无进展生存期与中位生存期分别为(7.26±1.42)、(21.32±2.33)个月,均长于对照组的(5.62±1.52)、(16.59±2.31)个月,差异有统计学意义(P<0.05);观察组的不良反应总发生率为4.00%,低于对照组的18.00%,差异有统计学意义(P<0.05)。结论采用卡培他滨维持治疗可有效延长患者生存期,提高治疗效果,显著改善患者预后,且安全性较高,不良反应较少,值得推广。Objective To analyze the efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer.Methods A total of 100 elderly patients with advanced triple negative breast cancer treated in Shangrao People′s Hospital from July 2016 to July 2019 were selected as the research objects,and were divided into control group(50 cases)and observation group(50 cases)by random number table method.The control group was treated with Docetaxel+Doxorubicin+Cyclophosphamide,the observation group was additionally given Capecitabine maintenance therapy.Treatment effect,progression-free survival,median survival and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 88.00%,higher than that of the control group 64.00%,the difference was statistically significant(P<0.05).The progression-free survival and median survival in the observation group were(7.26±1.42)and(21.32±2.33)months,respectively,longer than(5.62±1.52)and(16.59±2.31)months in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 4.00%,lower than 18.00%in the control group,the difference was statistically significant(P<0.05).Conclusion Capecitabine maintenance therapy can effectively prolong the survival of patients,improve the treatment effect,significantly improve the prognosis of patients,and high safety,less adverse reactions,worthy of promotion.

关 键 词：卡培他滨 老年晚期三阴性乳腺癌 疗效 安全性 应用价值 

分 类 号：R737.9[医药卫生—肿瘤]